← Back to all trials
Not Yet Recruiting
NCT07828353
A Clinical Study of REGEND001 for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Sex: All
Ages: 40 Years – 75 Years
Healthy volunteers: No
Phase: PHASE3
Enrollment: 102
Sponsor: Regend Therapeutics
Location: The First Affiliated Hospital of Guangzhou Medical University Guangzhou Guangdong
Summary
Chronic obstructive pulmonary disease (COPD) is a common, progressive, and heterogeneous respiratory disorder. It is associated with substantial morbidity and mortality worldwide, leading to progressive decline in lung function, impaired quality of life, and a significant healthcare burden. REGEND001, made from airway basal stem cells with ability to regenerate lung tissue, is promising to COPD treatment. In this study, a multicenter, randomized, blinded, placebo-parallel-controlled trial is performed to verify the efficacy and safety of REGEND001 in treatment of COPD patients with emphysema.
Eligibility Criteria
Inclusion Criteria:
* Male or female, aged 40-75 years；
* Diagnosed with COPD;
* Post-bronchodilator FEV1/FVC \
Source: ClinicalTrials.gov (NCT07828353). StuddyBuddy aggregates publicly available trial information.
